Generated by All in One SEO v4.9.9, this is an llms.txt file, used by LLMs to index the site.
# iECURE
Knocking Down Devastation. Inserting Hope.
## Sitemaps
- [XML Sitemap](https://iecure.com/sitemap.xml): Contains all public & indexable URLs for this website.
## Posts
- [Decreased rate of hyperammonemic crises in infants with neonatal-onset OTC deficiency post ECUR-506 administration: Preliminary update from the OTC-HOPE study](https://iecure.com/news/decreased-rate-of-hyperammonemic-crises-in-infants-with-neonatal-onset-otc-deficiency-post-ecur-506-administration-preliminary-update-from-the-otc-hope-study-2/)
- [iECURE named one of the 2026 Best Places to Work by the Philadelphia Business Journal for the third year in a row.](https://iecure.com/awards/iecure-named-one-of-the-2026-best-places-to-work-by-the-philadelphia-business-journal-for-the-third-year-in-a-row/)
- [Decreased rate of hyperammonemic crises in infants with neonatal-onset OTC deficiency post ECUR-506 administration: preliminary update from the OTC-HOPE study](https://iecure.com/news/decreased-rate-of-hyperammonemic-crises-in-infants-with-neonatal-onset-otc-deficiency-post-ecur-506-administration-preliminary-update-from-the-otc-hope-study/)
- [Sustained Clinical Response in First Patient Dosed With ECUR-506 One Year Post Discontinuation of Standard of Care](https://iecure.com/news/sustained-clinical-response-in-first-patient-dosed-with-ecur-506-one-year-post-discontinuation-of-standard-of-care/)
- [iECURE Reports Sustained Clinical Response in the First Patient Dosed with ECUR-506 & Reductions in the Annualized Rates of Hyperammonemic Events and Crises in the First Completed Cohort of ECUR-506 in Ongoing OTC-HOPE Trial](https://iecure.com/news/iecure-reports-sustained-clinical-response-in-the-first-patient-dosed-with-ecur-506-reductions-in-the-annualized-rates-of-hyperammonemic-events-and-crises-in-the-first-completed-cohort-of-ecur-506-i/)
- [iECURE Presents Preliminary Clinical Data from Ongoing Clinical Trial of ECUR-506 in Ornithine Transcarbamylase Deficiency at the ASGCT Annual Meeting](https://iecure.com/news/iecure-presents-preliminary-clinical-data-from-ongoing-clinical-trial-of-ecur-506-in-ornithine-transcarbamylase-deficiency-at-the-asgct-annual-meeting/)
- [Eighteen-Month Clinical Update from the First Patient Dosed in OTC-HOPE](https://iecure.com/news/eighteen-month-clinical-update-from-the-first-patient-dosed-in-otc-hope/)
- [iECURE to Present Preliminary Clinical Data from Ongoing OTC-HOPE Trial of ECUR-506 in Neonatal-Onset Ornithine Transcarbamylase Deficiency at the ASGCT and SIMD Annual Meetings](https://iecure.com/news/iecure-to-present-preliminary-clinical-data-from-ongoing-otc-hope-trial-of-ecur-506-in-neonatal-onset-ornithine-transcarbamylase-deficiency-at-the-asgct-and-simd-annual-meetings/)
- [iECURE Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of ECUR-506 Ahead of Planned BLA Submission](https://iecure.com/news/iecure-selected-for-u-s-fda-chemistry-manufacturing-and-controls-development-and-readiness-pilot-program-to-support-manufacturing-readiness-of-ecur-506-ahead-of-planned-bla-submission/)
- [iECURE Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ECUR-506 for Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency](https://iecure.com/news/iecure-receives-fda-regenerative-medicine-advanced-therapy-rmat-designation-for-ecur-506-for-neonatal-onset-ornithine-transcarbamylase-otc-deficiency/)
- [OTC-HOPE: The first in vivo, liver directed, AAV-mediated, gene insertion clinical trial in infants with Ornithine Transcarbamylase Deficiency](https://iecure.com/news/otc-hope-the-first-in-vivo-liver-directed-aav-mediated-gene-insertion-clinical-trial-in-infants-with-ornithine-transcarbamylase-deficiency/)
- [iECURE to Present OTC-HOPE Clinical Trial Data of ECUR-506 in Ornithine Transcarbamylase Deficiency at the European Society of Gene & Cell Therapy Annual Congress and the American Society of Human Genetics Annual Meeting](https://iecure.com/news/iecure-to-present-otc-hope-clinical-trial-data-of-ecur-506-in-ornithine-transcarbamylase-deficiency-at-the-european-society-of-gene-cell-therapy-annual-congress-and-the-american-society-of-human-gen/)
- [Initial Findings from the First Four Patients Enrolled in OTC-HOPE Clinical Trial: No Hyperammonemic Events in First Participant to Complete 24-week Study](https://iecure.com/news/initial-findings-from-the-first-four-patients-enrolled-in-otc-hope-clinical-trial-no-hyperammonemic-events-in-first-participant-to-complete-24-week-study/)
- [iECURE to Present Initial OTC-HOPE Clinical Trial Data of ECUR-506 in Ornithine Transcarbamylase Deficiency at 6th International Symposium on UCDs and 15th International Congress of Inborn Errors of Metabolism](https://iecure.com/news/iecure-to-present-initial-otc-hope-clinical-trial-data-of-ecur-506-in-ornithine-transcarbamylase-deficiency-at-6th-international-symposium-on-ucds-and-15th-international-congress-of-inborn-errors-of-m/)
- [iECURE named one of the 2025 Best Places to Work by the Philadelphia Business Journal for the second year in a row.](https://iecure.com/awards/iecure-named-one-of-the-2025-best-places-to-work-by-the-philadelphia-business-journal-for-the-second-year-in-a-row/)
- [iECURE shortlisted for the 2025 Citeline Awards for Excellence in Rare Disease Development.](https://iecure.com/awards/iecure-shortlisted-for-the-2025-citeline-awards-for-excellence-in-rare-disease-development/)
- [iECURE awarded Emerging Company of the Year by Life Sciences PA (LSPA).](https://iecure.com/awards/iecure-awarded-emerging-company-of-the-year-by-life-sciences-pa-lspa/)
- [iECURE recognized as Life Sciences & Healthcare Startup of the Year at the PACT 2024 Enterprise Awards. ](https://iecure.com/awards/iecure-recognized-as-life-sciences-healthcare-startup-of-the-year-at-the-pact-2024-enterprise-awards/)
- [iECURE named one of the 2024 Best Places to Work by the Philadelphia Business Journal.](https://iecure.com/awards/iecure-named-one-of-the-2024-best-places-to-work-by-the-philadelphia-business-journal/)
- [iECURE selected as a 2024 Inno Fire Awards Honoree for driving success and innovation in Greater Philadelphia.](https://iecure.com/awards/iecure-selected-as-a-2024-inno-fire-awards-honoree-for-driving-success-and-innovation-in-greater-philadelphia/)
- [iECURE named one of Fierce Biotech’s 2024 Fierce 15 by breaking barriers and defining the future of the industry.](https://iecure.com/awards/iecure-named-one-of-fierce-biotechs-2024-fierce-15-by-breaking-barriers-and-defining-the-future-of-the-industry/)
- [CEO Joseph Truitt recognized on the 2024 PharmaVoice100 list as an inspiring leader in the life sciences.](https://iecure.com/awards/ceo-joseph-truitt-recognized-on-the-2024-pharmavoice100-list-as-an-inspiring-leader-in-the-life-sciences/)
- [Initial clinical results from OTC-HOPE, the first in vivo, liver directed, AAV-mediated gene insertion study in neonatal OTC deficiency: complete clinical response observed in first male infant to receive ECUR-506 and complete 24-week Phase 1/2 study](https://iecure.com/news/initial-clinical-results-from-otc-hope-the-first-in-vivo/)
- [A First in Human, Single Arm, Open Label Phase 1/2 Study Evaluating ECUR-506 in Neonatal OTC Deficiency: Initial Observations](https://iecure.com/news/p008-a-first-in-human-single-arm-open-label-phase-1-2-study-evaluating-ecur-506-in-neonatal-otc-deficiency-initial-observations/)
- [iECURE to Present Initial OTC-HOPE Clinical Data of ECUR-506 in Ornithine Transcarbamylase Deficiency at Upcoming Medical Meetings](https://iecure.com/news/iecure-to-present-initial-otc-hope-clinical-data-of-ecur-506-in-ornithine-transcarbamylase-deficiency-at-upcoming-medical-meetings/)
- [iECURE Announces Presentation of Full Data for the First Infant Dosed with ECUR-506 in OTC-HOPE Phase 1/2 Clinical Trial at the 2025 ACMG Annual Clinical Genetics Meeting](https://iecure.com/news/iecure-announces-presentation-of-full-data-for-the-first-infant-dosed-with-ecur-506-in-otc-hope-phase-1-2-clinical-trial-at-the-2025-acmg-annual-clinical-genetics-meeting/)
- [iECURE to Present Initial Data from Phase 1/2 OTC-HOPE Clinical Trial in Ornithine Transcarbamylase Deficiency at ACMG Annual Clinical Genetics Meeting](https://iecure.com/news/iecure-to-present-initial-data-from-phase-1-2-otc-hope-clinical-trial-in-ornithine-transcarbamylase-deficiency-at-acmg-annual-clinical-genetics-meeting/)
- [This Startup Just Raised $50 Million To Deliver Gene Therapies For Rare Diseases](https://iecure.com/news/this-startup-just-raised-50-million-to-deliver-gene-therapies-for-rare-diseases/)
- [Gene editor may have cured infant of a deadly metabolic disorder](https://iecure.com/news/gene-editor-may-have-cured-infant-of-a-deadly-metabolic-disorder/)
- [Exclusive: First-of-its-kind infant DNA edit leads to apparent cure in disease that set back field 25 years ago](https://iecure.com/news/exclusive-first-of-its-kind-infant-dna-edit-leads-to-apparent-cure-in-disease-that-set-back-field-25-years-ago/)
- [Introducing Fierce Biotech's 2024 Fierce 15](https://iecure.com/news/introducing-fierce-biotechs-2024-fierce-15/)
- [iECURE Reports Complete Clinical Response in First Infant Dosed with its In Vivo Gene Editing Candidate ECUR-506 in an Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency](https://iecure.com/news/iecure-reports-complete-clinical-response-in-first-infant-dosed-with-its-in-vivo-gene-editing-candidate-ecur-506-in-an-ongoing-phase-1-2-clinical-trial-in-ornithine-transcarbamylase-otc-deficiency/)
- [University of Pennsylvania gene-editing spinout iEcure hits the FDA trifecta](https://iecure.com/news/university-of-pennsylvania-gene-editing-spinout-iecure-hits-the-fda-trifecta/)
- [iECURE Receives FDA Fast Track Designation for ECUR-506 for the Treatment of Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency](https://iecure.com/news/iecure-receives-fda-fast-track-designation-for-ecur-506-for-the-treatment-of-neonatal-onset-ornithine-transcarbamylase-otc-deficiency/)
- [Exclusive: Jim Wilson startup gets FDA green light for first test of gene editing in babies](https://iecure.com/news/exclusive-jim-wilson-startup-gets-fda-green-light-for-first-test-of-gene-editing-in-babies/)
- [iECURE Announces FDA Clearance of Investigational New Drug Application for ECUR-506 to Initiate OTC-HOPE Trial for Treatment of Neonatal Onset Ornithine Transcarbamylase Deficiency in the U.S.](https://iecure.com/news/iecure-announces-fda-clearance-of-investigational-new-drug-application-for-ecur-506-to-initiate-otc-hope-trial-for-treatment-of-neonatal-onset-ornithine-transcarbamylase-deficiency-in-the-u-s/)
- [iECURE Secures Approval from U.K. Medicines & Healthcare Products Regulatory Agency to Expand the OTC-HOPE Study of ECUR-506](https://iecure.com/news/iecure-secures-approval-from-u-k-medicines-healthcare-products-regulatory-agency-to-expand-the-otc-hope-study-of-ecur-506/)
- [iECURE Secures Clearance from Australian Therapeutic Goods Administration for its Clinical Trial Approval for the OTC-HOPE Phase 1/2 Study of ECUR-506](https://iecure.com/news/iecure-secures-clearance-from-australian-therapeutic-goods-administration-for-its-clinical-trial-approval-for-the-otc-hope-phase-1-2-study-of-ecur-506/)
- [iECURE Receives FDA Rare Pediatric Disease Designation for GTP-506, an Investigational Gene Editing Product Candidate for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency](https://iecure.com/news/iecure-receives-fda-rare-pediatric-disease-designation-for-gtp-506-an-investigational-gene-editing-product-candidate-for-the-treatment-of-ornithine-transcarbamylase-otc-deficiency/)
- [iECURE Receives FDA Orphan Drug Designation for GTP-506, an Investigational Gene Editing Product Candidate for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency](https://iecure.com/news/iecure-receives-fda-orphan-drug-designation-for-gtp-506-an-investigational-gene-editing-product-candidate-for-the-treatment-of-ornithine-transcarbamylase-otc-deficiency/)
- [Preclinical Data from iECURE’s GTP-506 Demonstrates Potential for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency](https://iecure.com/news/preclinical-data-from-iecures-gtp-506-demonstrates-potential-for-the-treatment-of-ornithine-transcarbamylase-otc-deficiency/)
- [iECURE Raises $65 Million to Advance In Vivo Gene Editing Programs for the Treatment of Rare Pediatric Liver Diseases](https://iecure.com/news/iecure-raises-65-million-to-advance-in-vivo-gene-editing-programs-for-the-treatment-of-rare-pediatric-liver-diseases/)
- [European Commission Grants Orphan Designation for iECURE’s Lead Product Candidate GTP-506 for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency](https://iecure.com/news/european-commission-grants-orphan-designation-for-iecures-lead-product-candidate-gtp-506-for-the-treatment-of-ornithine-transcarbamylase-otc-deficiency/)
- [iECURE Appoints Gabriel M. Cohn, M.D., as Chief Medical Officer](https://iecure.com/news/iecure-appoints-gabriel-m-cohn-m-d-as-chief-medical-officer/)
- [iECURE Enters Agreement with Center for Breakthrough Medicines (CBM) to Supply Materials for Future Clinical Programs](https://iecure.com/news/iecure-enters-agreement-with-center-for-breakthrough-medicines-cbm-to-supply-materials-for-future-clinical-programs/)
- [Nonhuman Primate Data from iECURE’s Knock-in In Vivo Gene Editing Approach for Deadly Urea Cycle Disorder to be Presented in Presidential Symposium at ASGCT 2022](https://iecure.com/news/nonhuman-primate-data-from-iecures-knock-in-in-vivo-gene-editing-approach-for-deadly-urea-cycle-disorder-to-be-presented-in-presidential-symposium-at-asgct-2022/)
- [iECURE Announces Presentation of Data on its Gene Editing Approach at the American Society of Cell and Gene Therapy Annual Meeting](https://iecure.com/news/iecure-announces-presentation-of-data-on-its-gene-editing-approach-at-the-american-society-of-cell-and-gene-therapy-annual-meeting/)
- [iECURE Appoints George Diaz, M.D., Ph.D., as VP, Therapeutic Area Lead for Urea Cycle Disorders](https://iecure.com/news/iecure-appoints-george-diaz-m-d-ph-d-as-vp-therapeutic-area-lead-for-urea-cycle-disorders/)
- [iECURE Launches With $50 Million Series A Financing to Develop In Vivo Gene Insertion Approaches for Devastating Diseases](https://iecure.com/news/iecure-launches-with-50-million-series-a-financing-to-develop-in-vivo-gene-insertion-approaches-for-devastating-diseases/)
- [iECURE Appoints Brian Di Donato to Board of Directors](https://iecure.com/news/iecure-appoints-brian-di-donato-to-board-of-directors/)
- [iECURE Partners to Develop Next-Generation Liver-Targeted Lipid Nanoparticles with University of Pennsylvania](https://iecure.com/news/iecure-partners-to-develop-next-generation-liver-targeted-lipid-nanoparticles-with-university-of-pennsylvania/)
- [iECURE Bolsters Senior Management Team with Appointment of David Garrett as Chief Financial Officer](https://iecure.com/news/iecure-bolsters-senior-management-team-with-appointment-of-david-garrett-as-chief-financial-officer/)
- [iECURE Expands Leadership Team with the Appointment of Mark Semanick as VP and Head of Technical Operations and Brad Dickerson as VP of Project Management & Patient Advocacy](https://iecure.com/news/iecure-expands-leadership-team-with-the-appointment-of-mark-semanick-as-vp-and-head-of-technical-operations-and-brad-dickerson-as-vp-of-project-management-patient-advocacy/)
- [The Tachi Yamada legacy tree continues to grow with a new gene editing biotech from Jim Wilson](https://iecure.com/news/the-tachi-yamada-legacy-tree-continues-to-grow-with-a-new-gene-editing-biotech-from-jim-wilson/)
- [34 healthcare and biotech startups that are set to take off in 2022, according to top investors](https://iecure.com/news/precision-biosciences-inks-gene-editing-deal-with-iecure/)
- [iECURE emerges with $50M to search for ‘holy grail’ and ‘untapped frontier’ of gene editing](https://iecure.com/news/iecure-emerges-with-50m-to-search-for-holy-grail-and-untapped-frontier-of-gene-editing/)
- [Jim Wilson launches liver disease gene-editing company iECURE with $50 million](https://iecure.com/news/jim-wilson-launches-liver-disease-gene-editing-company-iecure-with-50-million/)
- [Penn gene editing spinout iECURE just raised a $50M Series A](https://iecure.com/news/penn-gene-editing-spinout-iecure-just-raised-a-50m-series-a/)
- [Genetic meds pioneer James Wilson has a new startup, this time in gene editing](https://iecure.com/news/genetic-meds-pioneer-james-wilson-has-a-new-startup-this-time-in-gene-editing/)
## Pages
- [Home](https://iecure.com/) - Knocking down devastation. Inserting hope. At iECURE, we believe in vivo gene editing is the answer to meeting this immense patient need, and we believe reversing the course of these conditions is now within reach.
- [Approach](https://iecure.com/approach/) - Our approach to genome editing inserts a full, healthy copy of a gene responsible for disease and is therefore independent of the genetic mutations that cause the disease.
- [Programs](https://iecure.com/programs/) - Our programs are currently focused on developing in vivo gene insertion therapies for the treatment of rare pediatric liver diseases: indications where traditional gene therapy approaches have failed to produce durable responses, given the rapid cell division in children’s livers.
- [About](https://iecure.com/about/) - We're here to change patients' lives. Also, here to change genetic medicine as we know it today.
- [Careers](https://iecure.com/careers/) - Interested in joining our team of genetic medicine experts? Visit our Careers page for opportunities to join the team at iECURE.
- [Privacy Notice](https://iecure.com/privacy-notice/)
- [News](https://iecure.com/news/) - See the latest news and press releases from iECURE.
- [Contact](https://iecure.com/contact/) - Get in contact with iECURE.
- [Footer](https://iecure.com/footer/)
- [Cookie Notice](https://iecure.com/cookie-notice/)
- [Terms of Service](https://iecure.com/terms-of-service/)
- [Pipeline Build](https://iecure.com/pipeline-build/)
- [Expanded Access Policy](https://iecure.com/expanded-access-policy/)
- [404](https://iecure.com/page-not-found/)
## Portfolio Items
- [Patricia A. Ward](https://iecure.com/team/patricia-a-ward/)
- [Michelle Miller](https://iecure.com/team/michelle-miller/)
- [Taylor Chandler](https://iecure.com/team/taylor-chandler/)
- [Tay Salimullah](https://iecure.com/team/tay-salimullah/)
- [Robert Pietrusko, Pharm.D.](https://iecure.com/team/robert-pietrusko-pharm-d/)
- [Tom Woiwode, Ph.D.](https://iecure.com/team/tom-woiwode-ph-d/)
- [Heather Flynn](https://iecure.com/team/heather-flynn/)
- [Burt Adelman, M.D.](https://iecure.com/team/burt-adelman-m-d/)
- [James M. Wilson, M.D., Ph.D.](https://iecure.com/team/james-m-wilson-m-d-ph-d/)
- [Brad Dickerson](https://iecure.com/team/brad-dickerson/)
- [Jeff Kopesky](https://iecure.com/team/jeff-kopesky/)
- [Thomas White](https://iecure.com/team/thomas-white/)
- [Colten White](https://iecure.com/team/colten-white/)
- [Jane Fisher](https://iecure.com/team/jane-fisher/)
- [Mark J. Semanick](https://iecure.com/team/mark-j-semanick/)
- [Matthew Hall](https://iecure.com/team/matthew-hall/)
- [Maryann A. Toto, MSN, RAC](https://iecure.com/team/maryann-a-toto-msn-rac/)
- [Mike Burnham](https://iecure.com/team/mike-burnham/)
- [Karen Kuhn](https://iecure.com/team/karen-kuhn/)
- [Dave Lecher](https://iecure.com/team/dave-lecher/)
- [Donna Lutz](https://iecure.com/team/donna-lutz/)
- [Christine Rexer](https://iecure.com/team/christine-rexer/)
- [Eric Squinto](https://iecure.com/team/eric-squinto/)
- [George Alkire](https://iecure.com/team/george-alkire/)
- [Matthew Firuta](https://iecure.com/team/matthew-firuta/)
- [Sue McGoldrick](https://iecure.com/team/sue-mcgoldrick/)
- [Paul Firuta, MBA](https://iecure.com/team/paul-firuta-mba/)
- [Alex Monteith, MBA](https://iecure.com/team/alex-monteith-mba/)
- [David Garrett, MBA](https://iecure.com/team/david-garrett-mba/)
- [Gabriel M. Cohn, M.D., MBA](https://iecure.com/team/gabriel-m-cohn-m-d-mba/)
- [George Diaz, M.D., Ph.D.](https://iecure.com/team/george-diaz/)
- [Joseph Truitt, MBA](https://iecure.com/team/joseph-truitt-mba/)
- [Ray Camahort, Ph.D.](https://iecure.com/team/ray-camahort-phd/)
- [Derek Yuan, Ph.D.](https://iecure.com/team/derek-yuan-phd/)
- [Tal Zaks, M.D., Ph.D.](https://iecure.com/team/tal-zaks-md-phd/)
## Categories
- [news](https://iecure.com/category/news/)
- [press release](https://iecure.com/category/news/press-release/)
- [in the news](https://iecure.com/category/news/in-the-news/)
- [pubs & pres](https://iecure.com/category/news/pubs-pres/)
- [Awards](https://iecure.com/category/awards/)
## Portfolio Categories
- [Team](https://iecure.com/team_members/team/)
- [Leadership](https://iecure.com/team_members/leadership/)
- [BOD](https://iecure.com/team_members/bod/)
- [TeamMembers](https://iecure.com/team_members/teammembers/)
- [Advisors](https://iecure.com/team_members/advisors/)